Abstract | OBJECTIVE: METHODS: RESULTS: Thirteen patients (20%) had biopsy-proven myositis. The median duration of HIV infection prior to diagnosis of myositis was 4.3 years (range 0-11 years). Six patients had concomitant diffuse infiltrative lymphocytosis syndrome. There was no correlation of severity of weakness, stage of HIV infection, or retroviral treatment with the CK level at diagnosis. Eight patients received prednisone (60 mg/day) with 5 attaining complete resolution of myositis. The remaining 3 patients received immunosuppressive therapy ( azathioprine or methotrexate and intravenous immunoglobulin) and had normalization of strength and CK. Four patients had spontaneous resolution of their myositis without treatment. CONCLUSION: HIV-associated myositis occurs at any stage of HIV infection, has a relatively good prognosis, responds well to immunosuppressive therapy, and has little evidence of adverse outcome on the HIV infection.
|
Authors | Randall W Johnson, Francis M Williams, Salahuddin Kazi, Mazen M Dimachkie, John D Reveille |
Journal | Arthritis and rheumatism
(Arthritis Rheum)
Vol. 49
Issue 2
Pg. 172-8
(Apr 15 2003)
ISSN: 0004-3591 [Print] United States |
PMID | 12687507
(Publication Type: Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Anti-HIV Agents
- Anti-Inflammatory Agents
- Prednisolone
- Creatine Kinase
|
Topics |
- Adult
- Aged
- Anti-HIV Agents
(administration & dosage)
- Anti-Inflammatory Agents
(administration & dosage)
- Biopsy
- CD4-CD8 Ratio
- Creatine Kinase
(blood)
- Electromyography
- Female
- HIV Infections
(complications, diagnosis, drug therapy)
- Humans
- Longitudinal Studies
- Male
- Middle Aged
- Muscle Weakness
(drug therapy, pathology, virology)
- Polymyositis
(drug therapy, pathology, virology)
- Prednisolone
(administration & dosage)
- Prognosis
- Prospective Studies
- Treatment Outcome
|